Brokerages Set Alector, Inc. (NASDAQ:ALEC) PT at $14.50

Shares of Alector, Inc. (NASDAQ:ALEC) have been assigned an average rating of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $14.50.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $41.00 target price on shares of Alector in a research report on Wednesday, February 28th.

Alector Stock Performance

Shares of NASDAQ:ALEC opened at $5.64 on Friday. The firm has a market cap of $540.03 million, a PE ratio of -3.64 and a beta of 0.79. The firm’s 50 day simple moving average is $6.27 and its 200-day simple moving average is $6.23. Alector has a one year low of $3.66 and a one year high of $9.06.

Alector (NASDAQ:ALEC) last issued its earnings results on Tuesday, February 27th. The company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.31. The business had revenue of $15.19 million for the quarter, compared to analyst estimates of $8.35 million. Alector had a negative net margin of 134.34% and a negative return on equity of 77.15%. Equities research analysts predict that Alector will post -1.89 EPS for the current fiscal year.

Insider Activity at Alector

In related news, CEO Arnon Rosenthal sold 18,837 shares of Alector stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $6.92, for a total transaction of $130,352.04. Following the transaction, the chief executive officer now directly owns 2,000,380 shares of the company’s stock, valued at $13,842,629.60. The sale was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Arnon Rosenthal sold 18,837 shares of Alector stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $6.92, for a total transaction of $130,352.04. Following the transaction, the chief executive officer now directly owns 2,000,380 shares of the company’s stock, valued at $13,842,629.60. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Gary Romano sold 6,001 shares of Alector stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $6.92, for a total transaction of $41,526.92. Following the transaction, the insider now directly owns 196,313 shares in the company, valued at $1,358,485.96. The disclosure for this sale can be found here. Insiders have sold a total of 30,554 shares of company stock valued at $211,434 over the last ninety days. 14.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Alector

Several institutional investors have recently bought and sold shares of the company. Barclays PLC lifted its position in Alector by 24.0% during the third quarter. Barclays PLC now owns 138,826 shares of the company’s stock valued at $899,000 after purchasing an additional 26,856 shares during the period. Euclidean Capital LLC lifted its position in Alector by 33.3% during the third quarter. Euclidean Capital LLC now owns 1,307,858 shares of the company’s stock valued at $8,475,000 after purchasing an additional 326,964 shares during the period. Jacobs Levy Equity Management Inc. lifted its position in Alector by 33.5% during the third quarter. Jacobs Levy Equity Management Inc. now owns 778,077 shares of the company’s stock valued at $5,042,000 after purchasing an additional 195,411 shares during the period. Acadian Asset Management LLC lifted its position in Alector by 68.2% during the third quarter. Acadian Asset Management LLC now owns 153,266 shares of the company’s stock valued at $993,000 after purchasing an additional 62,155 shares during the period. Finally, Hsbc Holdings PLC lifted its position in Alector by 64.8% during the third quarter. Hsbc Holdings PLC now owns 36,807 shares of the company’s stock valued at $241,000 after purchasing an additional 14,472 shares during the period. 85.83% of the stock is currently owned by institutional investors and hedge funds.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.